All In Biotech

Free tool

FAERS Monitor: Jublia

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 203567 or its brand name (Jublia, Efinaconazole). Reports on generic versions are filed under their own applications.

Reports

1,962

Serious

727

37% of reports

Hospitalization

404

Death reported

108

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective423
  • fatigue244
  • pain234
  • headache214
  • asthenia209
  • drug hypersensitivity183
  • oedema peripheral180
  • anaemia172
  • pyrexia170
  • product dose omission issue166
  • asthma163
  • tremor163
  • cough162
  • lower respiratory tract infection161
  • musculoskeletal stiffness161

Reports by year received

View as table
YearReports
201427
2015314
2016329
2017163
2018133
201999
2020105
2021131
2022119
2023163
2024154
2025133
202692

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,197 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
lower respiratory tract infectionSignal16138.132.85,769
musculoskeletal stiffnessSignal16119.717.02,851
oedema peripheralSignal18015.913.82,501
asthmaSignal16315.513.42,202
tremorSignal16310.59.11,407
drug hypersensitivitySignal18310.18.81,512
anaemiaSignal1729.78.41,340
coughSignal1626.25.3710
product dose omission issueSignal1666.15.2705
astheniaSignal2096.05.2873
pyrexiaSignal1705.34.6593
painSignal2344.13.6558
headacheSignal2143.73.2424
drug ineffectiveSignal4233.43.2779
fatigueSignal2443.43.0418

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.